Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/25234545/ below:

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

Affiliations

• ¹ European School of Oncology & Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal. Electronic address: fatimacardoso@fundacaochampalimaud.pt.
• ² European School of Oncology, Milan, Italy; European School of Oncology, Bellinzona, Switzerland.
• ³ Breast Cancer Program, Memorial Sloan-Kettering Cancer Centre, New York, USA.
• ⁴ Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
• ⁵ Division of Oncology, Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland.
• ⁶ Department of Medical Oncology, Gustave-Roussy Institute, Villejuif, France.
• ⁷ Department of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil.
• ⁸ Department of Oncology/Radiumhemmet, Karolinska Institutet & Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden.
• ⁹ Department of Medical Oncology, Sandro Pitigliani Oncology Centre, Prato, Italy.
• ¹⁰ Breast Cancer Clinical Program, Duke Cancer Institute, Durham, USA.
• ¹¹ Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal.
• ¹² University Clinic Golnik, Medical Faculty Ljubljana, Ljubljana, Slovenia.
• ¹³ NK Basile Cancer Institute Breast Center of Excellence, American University of Beirut Medical Center, Beirut, Lebanon.
• ¹⁴ Brighton & Sussex Medical School, University of Sussex, Falmer, UK.
• ¹⁵ Breast Care Support Group, Europa Donna Malta, Mtarfa, Malta.
• ¹⁶ Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
• ¹⁷ BC Cancer Agency, Vancouver, Canada.
• ¹⁸ Departments of Health Services Research and Breast Medical Oncology, UT MD Anderson Cancer Center, Houston, USA.
• ¹⁹ APHP Tenon, IUC-UPMC, Francilian Breast Intergroup, AROME, Paris, France.
• ²⁰ Program of Breast Health, European Institute of Oncology, Milan, Italy.
• ²¹ Brustzentrum der Universität München, Munich, Denmark.
• ²² Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia.
• ²³ Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, USA.
• ²⁴ Sheba Medical Center, Tel Hashomer, Israel.
• ²⁵ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
• ²⁶ Europa Donna Cyprus, Nicosa, Cyprus.
• ²⁷ AdvancedBC.org, New York.
• ²⁸ University of Michigan Medical School and School of Public Health, Ann Arbor, USA.
• ²⁹ Europa Donna Sweden & Bröstcancerföreningarnas Riksorganisation, BRO, Sundbyberg, Sweden.
• ³⁰ Oncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona, Switzerland.
• ³¹ Department Medical Oncology, Division of Women's Cancers, Dana-Farber Cancer Institute, Boston, USA.
• ³² Jean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, France.
• ³³ Department of Medicine, Institut Jules Bordet, Brussels, Belgium.
• ³⁴ Department of Medicine, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco.
• ³⁵ Indiana University Medical CTR, Indianapolis, USA.
• ³⁶ Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle an der Saale, Germany.
• ³⁷ Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA.
• ³⁸ Sandton Oncology Centre, Johannesburg, South Africa.
• ³⁹ Department of Radiotherapy, Clinique des Grangettes, Geneva, Switzerland.
• ⁴⁰ Nursing Division, Health Board, Cardiff and Vale University, Cardiff, UK.
• ⁴¹ Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

• PMID: 25234545
• PMCID: PMC4176456
• DOI: 10.1093/annonc/mdu385

Item in Clipboard

F Cardoso et al. Ann Oncol. 2014 Oct.

• ¹ European School of Oncology & Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal. Electronic address: fatimacardoso@fundacaochampalimaud.pt.
• ² European School of Oncology, Milan, Italy; European School of Oncology, Bellinzona, Switzerland.
• ³ Breast Cancer Program, Memorial Sloan-Kettering Cancer Centre, New York, USA.
• ⁴ Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
• ⁵ Division of Oncology, Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland.
• ⁶ Department of Medical Oncology, Gustave-Roussy Institute, Villejuif, France.
• ⁷ Department of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil.
• ⁸ Department of Oncology/Radiumhemmet, Karolinska Institutet & Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden.
• ⁹ Department of Medical Oncology, Sandro Pitigliani Oncology Centre, Prato, Italy.
• ¹⁰ Breast Cancer Clinical Program, Duke Cancer Institute, Durham, USA.
• ¹¹ Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal.
• ¹² University Clinic Golnik, Medical Faculty Ljubljana, Ljubljana, Slovenia.
• ¹³ NK Basile Cancer Institute Breast Center of Excellence, American University of Beirut Medical Center, Beirut, Lebanon.
• ¹⁴ Brighton & Sussex Medical School, University of Sussex, Falmer, UK.
• ¹⁵ Breast Care Support Group, Europa Donna Malta, Mtarfa, Malta.
• ¹⁶ Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
• ¹⁷ BC Cancer Agency, Vancouver, Canada.
• ¹⁸ Departments of Health Services Research and Breast Medical Oncology, UT MD Anderson Cancer Center, Houston, USA.
• ¹⁹ APHP Tenon, IUC-UPMC, Francilian Breast Intergroup, AROME, Paris, France.
• ²⁰ Program of Breast Health, European Institute of Oncology, Milan, Italy.
• ²¹ Brustzentrum der Universität München, Munich, Denmark.
• ²² Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia.
• ²³ Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, USA.
• ²⁴ Sheba Medical Center, Tel Hashomer, Israel.
• ²⁵ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
• ²⁶ Europa Donna Cyprus, Nicosa, Cyprus.
• ²⁷ AdvancedBC.org, New York.
• ²⁸ University of Michigan Medical School and School of Public Health, Ann Arbor, USA.
• ²⁹ Europa Donna Sweden & Bröstcancerföreningarnas Riksorganisation, BRO, Sundbyberg, Sweden.
• ³⁰ Oncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona, Switzerland.
• ³¹ Department Medical Oncology, Division of Women's Cancers, Dana-Farber Cancer Institute, Boston, USA.
• ³² Jean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, France.
• ³³ Department of Medicine, Institut Jules Bordet, Brussels, Belgium.
• ³⁴ Department of Medicine, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco.
• ³⁵ Indiana University Medical CTR, Indianapolis, USA.
• ³⁶ Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle an der Saale, Germany.
• ³⁷ Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA.
• ³⁸ Sandton Oncology Centre, Johannesburg, South Africa.
• ³⁹ Department of Radiotherapy, Clinique des Grangettes, Geneva, Switzerland.
• ⁴⁰ Nursing Division, Health Board, Cardiff and Vale University, Cardiff, UK.
• ⁴¹ Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

• PMID: 25234545
• PMCID: PMC4176456
• DOI: 10.1093/annonc/mdu385

Item in Clipboard

No abstract available

PubMed Disclaimer

• ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).

  Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E; European School of Oncology; European Society of Medical Oncology. Cardoso F, et al. Breast. 2014 Oct;23(5):489-502. doi: 10.1016/j.breast.2014.08.009. Epub 2014 Sep 20. Breast. 2014. PMID: 25244983 No abstract available.

• 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.

  Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. Cardoso F, et al. Ann Oncol. 2018 Aug 1;29(8):1634-1657. doi: 10.1093/annonc/mdy192. Ann Oncol. 2018. PMID: 30032243 Free PMC article. No abstract available.

• 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).

  Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP. Cardoso F, et al. Ann Oncol. 2020 Dec;31(12):1623-1649. doi: 10.1016/j.annonc.2020.09.010. Epub 2020 Sep 23. Ann Oncol. 2020. PMID: 32979513 Free PMC article. No abstract available.

• ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3).

  Paluch-Shimon S, Pagani O, Partridge AH, Abulkhair O, Cardoso MJ, Dent RA, Gelmon K, Gentilini O, Harbeck N, Margulies A, Meirow D, Pruneri G, Senkus E, Spanic T, Sutliff M, Travado L, Peccatori F, Cardoso F. Paluch-Shimon S, et al. Breast. 2017 Oct;35:203-217. doi: 10.1016/j.breast.2017.07.017. Epub 2017 Aug 17. Breast. 2017. PMID: 28822332

• Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.

  Yeo W, Ueno T, Lin CH, Liu Q, Lee KH, Leung R, Naito Y, Park YH, Im SA, Li H, Yap YS, Lu YS; Asian Breast Cancer Cooperative Group. Yeo W, et al. Breast Cancer Res Treat. 2019 Oct;177(3):549-559. doi: 10.1007/s10549-019-05318-5. Epub 2019 Jul 4. Breast Cancer Res Treat. 2019. PMID: 31270763 Review.

• Antrodia cinnamomea is a potentially effective complementary medicine for adjuvant therapy against breast cancer with bone metastasis: A case report.

  Long H, Hu CT, Prijatelj V, Weng CF. Long H, et al. Medicine (Baltimore). 2020 Jul 2;99(27):e20808. doi: 10.1097/MD.0000000000020808. Medicine (Baltimore). 2020. PMID: 32629666 Free PMC article.

• Subcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German Centers.

  Jackisch C, Müller V, Dall P, Neumeister R, Park-Simon TW, Ruf-Dördelmann A, Seiler S, Tesch H, Ataseven B. Jackisch C, et al. Geburtshilfe Frauenheilkd. 2015 Jun;75(6):566-573. doi: 10.1055/s-0035-1546172. Geburtshilfe Frauenheilkd. 2015. PMID: 26166837 Free PMC article. Review.

• Gum Acacia Functionalized Colloidal Gold Nanoparticles of Letrozole as Biocompatible Drug Delivery Carrier for Treatment of Breast Cancer. Aldawsari HM, Singh S, Alhakamy NA, Bakhaidar RB, Halwani AA, Badr-Eldin SM. Aldawsari HM, et al. Pharmaceutics. 2021 Sep 24;13(10):1554. doi: 10.3390/pharmaceutics13101554. Pharmaceutics. 2021. PMID: 34683847 Free PMC article. Retracted.
• The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer.

  Pejerrey SM, Dustin D, Kim JA, Gu G, Rechoum Y, Fuqua SAW. Pejerrey SM, et al. Horm Cancer. 2018 Aug;9(4):215-228. doi: 10.1007/s12672-017-0306-5. Epub 2018 May 7. Horm Cancer. 2018. PMID: 29736566 Free PMC article. Review.

• Evaluation of multiple transcriptomic gene risk signatures in male breast cancer.

  Bayani J, Poncet C, Crozier C, Neven A, Piper T, Cunningham C, Sobol M, Aebi S, Benstead K, Bogler O, Dal Lago L, Fraser J, Hilbers F, Hedenfalk I, Korde L, Linderholm B, Martens J, Middleton L, Murray M, Kelly C, Nilsson C, Nowaczyk M, Peeters S, Peric A, Porter P, Schröder C, Rubio IT, Ruddy KJ, van Asperen C, Van Den Weyngaert D, van Deurzen C, van Leeuwen-Stok E, Vermeij J, Winer E, Giordano SH, Cardoso F, Bartlett JMS. Bayani J, et al. NPJ Breast Cancer. 2021 Jul 26;7(1):98. doi: 10.1038/s41523-021-00301-0. NPJ Breast Cancer. 2021. PMID: 34312396 Free PMC article.

1. 1. Cardoso F. Metastatic breast cancer patients: the forgotten heroes! The Breast. 2009;18:271–272. - PubMed
2. 1. Largillier R, Ferrero J-M, Doyen J, et al. Prognostic factors in 1038 women with metastatic breast cancer. Ann Oncol. 2008;19:2012–2019. - PMC - PubMed
3. 1. Andre F, Slimane K, Bachelot T, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004;22:3302–3308. - PubMed
4. 1. Sundquist M, Eriksson Z, Tejler G, et al. Trends in survival in metastatic breast cancer. Eur J Cancer. 2010;8(3):191. (abstract 453)
5. 1. Foukakis T, Fornander T, Lekberg T, et al. Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. Breast Cancer Res Treat. 2011;130(2):553–560. - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3